MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation

This publication has 27 references indexed in Scilit:

• Debrisoquine 4-Hydroxylase: Characterization of a New P450 Gene Subfamily, Regulation, Chromosomal Mapping, and Molecular Analysis of the DA Rat Polymorphism
  DNA, 1987
• The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation
  Xenobiotica, 1986
• ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINE
  The Lancet, 1985
• Does an endogenous methylpyridinium analogue cause Parkinson's disease?
  Journal of Pharmacy and Pharmacology, 1985
• Mechanism of MPTP toxicity: more answers, more questions
  Trends in Pharmacological Sciences, 1985
• Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers
  Biochemical and Biophysical Research Communications, 1984
• Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
  Science, 1983
• Defective Oxidation of Drugs
  Clinical Pharmacokinetics, 1982
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
  Nature, 1970
• REGIONAL STUDIES OF CATECHOLAMINES IN THE RAT BRAIN‐I
  Journal of Neurochemistry, 1966